The merger will create a clinical-stage cancer-focused biotech with funding that will last into 2024 and pipeline headed by ATX-101, a peptide-targeting PCNA being developed by APIM in clinical trials for platinum-sensitive ovarian cancer and sarcoma.
Nordic Nanovector was hit hard in July when the PARADIGME study of Betalutin (177Lu lilotomab satetraxetan) – an anti-CD37 antibody radionuclide conjugate being tested as a third-line therapy for follicular lymphoma – was abandoned after being plagued with recruitment issues.